dtpcrm - Dose Transition Pathways for Continual Reassessment Method
Provides the dose transition pathways (DTP) to project in
advance the doses recommended by a model-based design for
subsequent patients (stay, escalate, deescalate or stop early)
using all the accumulated toxicity information; See Yap et al
(2017) <doi: 10.1158/1078-0432.CCR-17-0582>. DTP can be used as
a design and an operational tool and can be displayed as a
table or flow diagram. The 'dtpcrm' package also provides the
modified continual reassessment method (CRM) and time-to-event
CRM (TITE-CRM) with added practical considerations to allow
stopping early when there is sufficient evidence that the
lowest dose is too toxic and/or there is a sufficient number of
patients dosed at the maximum tolerated dose.